Risk factors

Public-company compliance costs and management time are now emphasized, including higher costs after emerging-growth-company status ends.

Shoulder Innovations is an early-stage medical device company facing recurring net losses and holding $15,000 thousand in debt under its Trinity Loan Agreement. The company depends heavily on market adoption of its shoulder implant systems, third-party reimbursement, and a network of independent distributors.

Government shutdowns and procurement dependence dominate risks to revenue from U.S. federal contracts and TPOXX.

Severe going concern doubt driven by $55,924,814 in net losses for 2025 and only $25,737,221 in cash. Facing a Nasdaq delisting notice after 39 consecutive days under $1.00 per share. Hit with securities class action litigation and derivative lawsuits regarding nimacimab statements in late 2025 and early 2026.

Updates expand references to Fast Track Designation for TARA-002 in pediatric lymphatic malformations and adjust warrant details.

Net operating losses surged from $19.5 million to $56.4 million, driving increased reliance on equity financing and share dilution.

TWFG highlights expanded risks around artificial intelligence adoption, cybersecurity, and vendor dependencies in insurance distribution.

Fleet modernization and multi-year business transformation drive ongoing financial variability and high capital requirements.

Company issued $120 million in convertible notes due 2031, adding debt and dilution risks. Operations focus on restarting Lost Creek and building Shirley Basin in 2026. Inflationary pressures have stabilized somewhat since the post-pandemic period.

Valhi updated disclosures to reflect the LPC acquisition merger, reduced real estate development obligations in Henderson, Nevada, and added customer concentration risks for its Component Products Segment.

Voyager Technologies carries heavy risks from unproven space station development, substantial capital requirements, and ongoing net losses. The business depends heavily on government contracts, complex supply chains, and high-risk space technology operations.

Expanded disclosures cover new competitive threats from approved treatments like Teplizumab and Lantidra. Details added regarding share issuances, private placements, and governance amendments involving MacAndrews. Tax receivable agreement risks updated to reflect potential excess cash payments to M&F.